Literature DB >> 24816987

Epigenetics in esophageal cancers.

Theresa D Ahrens1, Martin Werner, Silke Lassmann.   

Abstract

Esophageal cancers are a challenging upper gastrointestinal tract tumor entity for interdisciplinary oncology. For the two main histotypes, namely esophageal squamous cell carcinomas and Barrett's adenocarcinomas, several genetic aberrations have been shown to contribute to carcinogenesis and progression as well as to represent potential novel targets for therapeutic intervention. This is paralleled by growing insight into epigenetic alterations of esophageal cancers. Studies involving the analyses of human tissue specimens predominantly describe altered patterns of miRNA expression, DNA methylation patterns, and histone marks levels. This review provides a critical update on this increasing knowledge of epigenetic alteration in esophageal cancers by specifically focusing on the translational aspects of epigenetic analyses from human tissue specimens.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816987     DOI: 10.1007/s00441-014-1876-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  15 in total

1.  Elevated expression of MDR1 associated with Line-1 hypomethylation in esophageal squamous cell carcinoma.

Authors:  Jing Zhu; Yang Ling; Yun Xu; Ming-Zhu Lu; Yong-Ping Liu; Chang-Song Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.

Authors:  Theresa D Ahrens; Sylvia Timme; Jens Hoeppner; Jenny Ostendorp; Sina Hembach; Marie Follo; Ulrich T Hopt; Martin Werner; Hauke Busch; Melanie Boerries; Silke Lassmann
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

3.  Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.

Authors:  Theresa D Ahrens; Sylvia Timme; Jenny Ostendorp; Lioudmilla Bogatyreva; Jens Hoeppner; Ulrich T Hopt; Dieter Hauschke; Martin Werner; Silke Lassmann
Journal:  Lab Invest       Date:  2015-12-21       Impact factor: 5.662

4.  Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma.

Authors:  Dongping Wu; Xiaoying Chen; Yan Xu; Haiyong Wang; Guangmao Yu; Luping Jiang; Qingxiao Hong; Shiwei Duan
Journal:  Oncol Lett       Date:  2017-02-22       Impact factor: 2.967

Review 5.  Emerging therapeutic targets in esophageal adenocarcinoma.

Authors:  Puja Gaur; Clayton R Hunt; Tej K Pandita
Journal:  Oncotarget       Date:  2016-07-26

6.  Role of MLH1 methylation in esophageal cancer carcinogenesis and its clinical significance.

Authors:  Jinyun Li; Dong Ye; Lei Wang; Yingying Peng; Qun Li; Hongxia Deng; Chongchang Zhou
Journal:  Onco Targets Ther       Date:  2018-02-01       Impact factor: 4.147

7.  Expression of methylation-modulated tumor-related genes in endoscopically resected early esophageal squamous neoplasia.

Authors:  Kohei Hosoda; Kazuo Yashima; Akihiro Tamoto; Sohei Yamamoto; Soichiro Kawata; Yuichiro Ikebuchi; Kazuya Matsumoto; Koichiro Kawaguchi; Kenichi Harada; Yoshikazu Murawaki; Hajime Isomoto
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

8.  mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes.

Authors:  Judong Luo; Wenjie Wang; Yiting Tang; Dandan Zhou; Yi Gao; Qi Zhang; Xifa Zhou; Hui Zhu; Ligang Xing; Jinming Yu
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

9.  NDRG4 hypermethylation is a potential biomarker for diagnosis and prognosis of gastric cancer in Chinese population.

Authors:  Xiaoying Chen; Yong Yang; Jing Liu; Bin Li; Yan Xu; Cong Li; Qi Xu; Guili Liu; Yingmin Chen; Jieer Ying; Shiwei Duan
Journal:  Oncotarget       Date:  2017-01-31

Review 10.  The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma.

Authors:  Kai Ma; Baoping Cao; Mingzhou Guo
Journal:  Clin Epigenetics       Date:  2016-04-22       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.